Hematological Malignancies Market

Hematological Malignancies Market (Disease Condition - Leukemia, Lymphoma, and Myeloma; Therapy - Chemotherapy, Immunotherapy, and Targeted Therapy; Distribution Channel - Hospital Pharmacies, Medical Stores, and E-commerce Platform) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • Rep Id : TMRGL4580
  • Published On : Nov 2016
  • No. of Pages : 152
  • Category : Pharmaceutical

1. Preface
     1.1. Research Scope
     1.2. Market Segmentation
     1.3. Research Objectives
     1.4. Key Questions Answered

2. Assumptions and Research Methodology
     2.1. Report Assumptions
     2.2. Acronyms Used
     2.3. Research Methodology

3. Executive Summary
     3.1. Global Hematological malignancies Market Snapshot
     3.2. Market Opportunity Map

4. Market Overview
     4.1. Product Overview
     4.2. Key Industry Events
     4.3. Death Rate of Leukemia, by Country
     4.4. Death Rate of Cancer, by Country

5. Market Dynamics
     5.1. Drivers and Restraints Snapshot Analysis
     5.2. Drivers
     5.3. Restraints
     5.4. Opportunities
     5.5. Opportunity Analysis
     5.6. Porter’s Analysis
     5.7. Pipeline Analysis (Phase III) till 2024

6. Global Hematological Malignancies Market Analysis, by Disease Condition
     6.1. Key Findings
     6.2. Introduction
     6.3. Leukemia
     6.4. Lymphoma
     6.5. Myeloma
     6.6. Key Trends
     6.7. Market Attractiveness Analysis

7. Global Hematological Malignancies Market Analysis, by Therapy
     7.1. Key Findings
     7.2. Introduction
     7.3. Chemotherapy
     7.4. Immunotherapy
     7.5. Targeted Therapy
     7.6. Key Trends
     7.7. Market Attractiveness Analysis

8. Global Hematological Malignancies Market Analysis, by Distribution Channel
     8.1. Key Findings
     8.2. Introduction
     8.3. Hospital Pharmacies
     8.4. Medical Stores
     8.5. E-commerce Platform
     8.6. Key Trend Analysis
     8.7. Market Attractiveness Analysis

9. Global Hematological Malignancies Market Analysis, by Region
     9.1. North America
     9.2. Europe
     9.3. Asia Pacific
     9.4. Latin America
     9.5. Middle East & Africa
     9.6. Market Attractiveness Analysis

10. North America Hematological malignancies Market Analysis
     10.1. North America Hematological Malignancies Market Size Forecast, By Country, 2016-2024
     10.2. North America Hematological Malignancies Market Size Forecast, By Disease Condition, 2016-2024
     10.3. North America Hematological Malignancies Market Size Forecast, By Therapy, 2016-2024
     10.4. North America Hematological Malignancies Market Size Forecast, By Distribution Channel, 2016-2024
     10.5. North America Hematological Malignancies Market Attractiveness Analysis, 2016-2024

11. Europe Hematological Malignancies Market Analysis
     11.1. Europe Hematological Malignancies Market Size Forecast, By Country, 2016-2024
     11.2. Europe Hematological Malignancies Market Size Forecast, By Disease Condition, 2016-2024
     11.3. Europe Hematological Malignancies Market Size Forecast, By Therapy, 2016-2024
     11.4. Europe Hematological Malignancies Market Size Forecast, By Distribution Channel, 2016-2024
     11.5. Europe Hematological Malignancies Market Attractiveness Analysis, 2016-2024

12. Asia Pacific Hematological Malignancies Market Analysis
     12.1. Asia Pacific Hematological Malignancies Market Size Forecast, By Country, 2016-2024
     12.2. Asia Pacific Hematological Malignancies Market Size Forecast, By Disease Condition, 2016-2024
     12.3. Asia Pacific Hematological Malignancies Market Size Forecast, By Therapy, 2016-2024
     12.4. Asia Pacific Hematological Malignancies Market Size Forecast, By Distribution Channel, 2016-2024
     12.5. Asia Pacific Hematological Malignancies Market Attractiveness Analysis, 2016-2024

13. Latin America Hematological Malignancies Market Analysis
     13.1. Latin America Hematological Malignancies Market Size Forecast, By Country, 2016-2024
     13.2. Latin America Hematological Malignancies Market Size Forecast, By Disease Condition, 2016-2024
     13.3. Latin America Hematological Malignancies Market Size Forecast, By Therapy, 2016-2024
     13.4. Latin America Hematological Malignancies Market Size Forecast, By Distribution Channel, 2016-2024
     13.5. Latin America Hematological Malignancies Market Attractiveness Analysis, 2016-2024

14. Middle East & Africa Hematological Malignancies Market Analysis
     14.1. Middle East & Africa Hematological Malignancies Market Size Forecast, By Country, 2016-2024
     14.2. Middle East & Africa Hematological Malignancies Market Size Forecast, By Disease Condition, 2016-2024
     14.3. Middle East & Africa Hematological Malignancies Market Size Forecast, By Therapy, 2016-2024
     14.4. Middle East & Africa Hematological Malignancies Market Size Forecast, By Distribution Channel, 2016-2024
     14.5. Middle East & Africa Hematological Malignancies Market Attractiveness Analysis, 2016-2024

15. Competitive Landscape
     15.1. Hematological Malignancies Market Share Analysis By Company (2015)
     15.2. Competition Matrix
             15.2.1. Teva Pharmaceutical Industries Ltd.
             15.2.2. GlaxoSmithKline plc
             15.2.3. Johnson & Johnson
             15.2.4. Bristol Myers Squibb
             15.2.5. F. Hoffmann-La Roche Ltd. 
             15.2.6. Merck & Co., Inc. 
             15.2.7. Novartis AG 
             15.2.8. Pfizer, Inc. 

16. Company Profiles
     16.1. AbbVie, Inc.
             16.1.1. Company Details
             16.1.2. Company Description
             16.1.3. Business Overview
             16.1.4. SWOT Analysis
             16.1.5. Financial Analysis
             16.1.6. Strategic Overview
     16.2. Bristol-Myers Squibb Company
             16.2.1. Company Details
             16.2.2. Company Description
             16.2.3. Business Overview
             16.2.4. SWOT Analysis
             16.2.5. Financial Analysis
             16.2.6. Strategic Overview
     16.3. Celgene Corporation
             16.3.1. Company Details
             16.3.2. Company Description
             16.3.3. Business Overview
             16.3.4. SWOT Analysis
             16.3.5. Financial Analysis
             16.3.6. Strategic Overview
     16.4. F. Hoffmann-La Roche Ltd.
             16.4.1. Company Details
             16.4.2. Company Description
             16.4.3. Business Overview
             16.4.4. SWOT Analysis
             16.4.5. Financial Analysis
             16.4.6. Strategic Overview
     16.5. GlaxoSmithKline plc
             16.5.1. Company Details
             16.5.2. Company Description
             16.5.3. Business Overview
             16.5.4. SWOT Analysis
             16.5.5. Financial Analysis
             16.5.6. Strategic Overview
     16.6. Johnson & Johnson
             16.6.1. Company Details
             16.6.2. Company Description
             16.6.3. Business Overview
             16.6.4. SWOT Analysis
             16.6.5. Financial Analysis
             16.6.6. Strategic Overview
     16.7. Novartis AG
             16.7.1. Company Details
             16.7.2. Company Description
             16.7.3. Business Overview
             16.7.4. SWOT Analysis
             16.7.5. Financial Analysis
             16.7.6. Strategic Overview
     16.8. Pfizer, Inc.
             16.8.1. Company Details
             16.8.2. Company Description
             16.8.3. Business Overview
             16.8.4. SWOT Analysis
             16.8.5. Financial Analysis
             16.8.6. Strategic Overview
     16.9. Teva Pharmaceutical Industries Ltd.
             16.9.1. Company Details
             16.9.2. Company Description
             16.9.3. Business Overview
             16.9.4. SWOT Analysis
             16.9.5. Financial Analysis
             16.9.6. Strategic Overview

List of Tables

TABLE 1 Global Hematological Malignancies Market Size (US$ Mn) Forecast, by Pipeline Molecule, till 2024
TABLE 2 Global Hematological Malignancies Market Size (US$ Mn) Forecast, by Disease Condition, 2016–2024
TABLE 3 Global Hematological Malignancies Market Size (US$ Mn) Forecast, by Therapy, 2016–2024
TABLE 4 Global Hematological Malignancies Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
TABLE 5 Global Hematological Malignancies Market Size (US$ Mn) Forecast, by Region, 2016–2024
TABLE 6 North America Hematological Malignancies Market Size (US$ Mn) Forecast, by Country, 2016–2024
TABLE 7 North America Hematological Malignancies Market Size (US$ Mn) Forecast, by Disease Condition, 2016–2024
TABLE 8 North America Hematological Malignancies Market Size (US$) Forecast, by Therapy, 2016–2024
TABLE 9 North America Hematological Malignancies Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
TABLE 10 Europe Hematological Malignancies Market Size (US$ Mn) Forecast, by Country, 2016–2024
TABLE 11 Europe Hematological Malignancies Market Size (US$ Mn) Forecast, by Disease Condition, 2016–2024
TABLE 12 Europe Hematological Malignancies Market Size (US$) Forecast, by Therapy, 2016–2024
TABLE 13 Europe Hematological Malignancies Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
TABLE 14 Asia Pacific Hematological Malignancies Market Size (US$ Mn) Forecast, by Country, 2016–2024
TABLE 15 Asia Pacific Hematological Malignancies Market Size (US$ Mn) Forecast, by Disease Condition, 2016–2024
TABLE 16 Asia Pacific Hematological Malignancies Market Size (US$) Forecast, by Therapy, 2016–2024
TABLE 17 Asia Pacific Hematological Malignancies Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
TABLE 18 Latin America Hematological Malignancies Market Size (US$ Mn) Forecast, by Country, 2016–2024
TABLE 19 Latin America Hematological Malignancies Market Size (US$ Mn) Forecast, by Disease Condition, 2016–2024
TABLE 20 Latin America Hematological Malignancies Market Size (US$) Forecast, by Therapy, 2016–2024
TABLE 21 Latin America Hematological Malignancies Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
TABLE 22 MEA Hematological Malignancies Market Size (US$ Mn) Forecast, by Country, 2016–2024
TABLE 23 MEA Hematological Malignancies Market Size (US$ Mn) Forecast, by Disease Condition, 2016–2024
TABLE 24 MEA Hematological Malignancies Market Size (US$) Forecast, by Therapy, 2016–2024

List of Figures

FIG. 1 Global Hematological Malignancies Market Value Share Analysis, by Disease Condition, 2015 and 2024
FIG. 2 Global Leukemia Market Revenue (US$ Mn), 2014–2024
FIG. 3 Global Lymphoma Market Revenue (US$ Mn), 2014–2024
FIG. 4 Global Myeloma Market, Revenue (US$ Mn), 2014–2024
FIG. 5 Hematological Malignancies Market Attractiveness Analysis, by Disease Condition, 2015
FIG. 6 Global Hematological Malignancies Market Value Share Analysis, by Therapy, 2015 and 2024
FIG. 7 Global Chemotherapy Market Revenue (US$ Mn), 2014–2024
FIG. 8 Global Immunotherapy Market Revenue (US$ Mn), 2014–2024
FIG. 9 Global Targeted Therapy Market, Revenue (US$ Mn), 2014–2024
FIG. 10 Hematological Malignancies Market Attractiveness Analysis, by Therapy, 2015
FIG. 11 Global Hematological Malignancies Market Value Share Analysis, by Distribution Channel, 2015 and 2024
FIG. 12 Global Hospital Pharmacies Market Revenue (US$ Mn), 2014–2024
FIG. 13 Global Medical Stores Market Revenue (US$ Mn), 2014–2024
FIG. 14 Global E-commerce Market, Revenue (US$ Mn), 2014–2024
FIG. 15 Hematological Malignancies Market Attractiveness Analysis, by Distribution Channel, 2015
FIG. 16 North America Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 17 Europe Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 18 APAC Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 19 Latin America Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 20 MEA Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 21 Global Hematological Malignancies Market Attractiveness Analysis, by Region
FIG. 22 U.S. Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 23 Canada Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 24 North America Hematological Malignancies Market Attractiveness Analysis, by Country
FIG. 25 North America Hematological Malignancies Market Attractiveness Analysis, by Disease Condition
FIG. 26 North America Hematological Malignancies Market Attractiveness Analysis, by Therapy
FIG. 27 North America Hematological Malignancies Market Attractiveness Analysis, by Distribution Channel
FIG. 28 Germany Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 29 France Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 30 The U.K. Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 31 Italy Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 32 Spain Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 33 Rest of Europe Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 34 Europe Hematological Malignancies Market Attractiveness Analysis, by Country
FIG. 35 Europe Hematological Malignancies Market Attractiveness Analysis, by Disease Condition
FIG. 36 Europe Hematological Malignancies Market Attractiveness Analysis, by Therapy
FIG. 37 Europe Hematological Malignancies Market Attractiveness Analysis, by Distribution Channel
FIG. 38 Japan Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 39 China Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 40 India Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 41 Rest of APAC Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 42 Asia Pacific Hematological Malignancies Market Attractiveness Analysis, by Country
FIG. 43 Asia Pacific Hematological Malignancies Market Attractiveness Analysis, by Disease Condit
FIG. 44 Asia Pacific Hematological Malignancies Market Attractiveness Analysis, by Therapy
FIG. 45 Asia Pacific Hematological Malignancies Market Attractiveness Analysis, by Distribution Channel
FIG. 46 Brazil Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 47 Mexico Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 48 Rest of LATAM Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 49 Latin America Hematological Malignancies Market Attractiveness Analysis, by Country
FIG. 50 Latin America Hematological Malignancies Market Attractiveness Analysis, by Disease Condition
FIG. 51 Latin America Hematological Malignancies Market Attractiveness Analysis, by Therapy
FIG. 52 Latin America Hematological Malignancies Market Attractiveness Analysis, by Distribution Channel
FIG. 53 South Africa Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 54 Saudi Arabia Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 55 Rest of MEA Hematological Malignancies Market Size (US$ Mn) Forecast, 2016–2024
FIG. 56 MEA Hematological Malignancies Market Attractiveness Analysis, by Country
FIG. 57 MEA Hematological Malignancies Market Attractiveness Analysis, by Disease Condition
FIG. 58 MEA Hematological Malignancies Market Attractiveness Analysis, by Therapy
FIG. 59 MEA Hematological Malignancies Market Attractiveness Analysis, by Distribution Channel
FIG. 60 Hematological Malignancies Market Share Analysis, by Company (2015)

.